News
We send the latest information from SMC Laboratories.
Introducing our new model: DDC-induced liver injury model
We introduce the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver injury model*, a well-known mod…
Reserve a non-clinical pharmacology consultation with us at BIO KOREA 2022!
We will join BIO KOREA 2022 International Convention, one of the biggest bio-health conventions in Asia. BIO K…
kk
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis…
Introduction of the paper using our UUO model
We would like to introduce a paper published by our client using Chronic kidney disease model. &…
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunct…
Drug efficacy studies using multiple mouse models to replicate human disease.
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of…
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related de…
Drug efficacy study in NASH mouse model
We would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) mode…
Published papers with IPF model
We would like to share with you some examples of studies that our clients have often asked us about using the …
Why is Chronic Kidney Disease so hard to research?
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, ho…